PRESSEMITTEILUNGEN

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET Berlin, Germany, and Seattle, WA, U.S.A., December 9, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer [...]

Continue reading

Adhoc, Berlin Germany, Cancer Cases, Clinical Performance, Clinical Validation, Colonoscopy, Colorectal, Colorectal Cancer, Diagnostic Company, Disease Specificity, Eans, Epigenomics Ag, Independent Laboratories, Molecular Diagnostics, Plasma Samples, Prime Standard, Regulatory Approval, Screening Guidelines, Study Subjects, Validation Study

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Research & Development 02.07.2010 Vienna (Austria)/Gaithersburg (USA), July 2, 2010 – Intercell AG (VSE: ICLL) today announced the results of a Phase II clinical trial of its investigational Vaccine [...]

Continue reading

Adjuvant, Antigen, Avian Influenza, Clinical Phase, Dependent Response, Enhancement Patch, H5n1 Influenza, H5n1 Vaccine, Influenza, Influenza Vaccine, Intercell, Investigational Vaccine, Optimal Combination, Pandemic Influenza, Proof Of Concept, Safety Profile, Study Subjects, Titers, U S Department Of Health And Human Services, Vienna Austria

Differences in analytical instrument read-out requires verification and potential retesting of samples measured in laboratory with deviating results Top-line data expected still in Q1 2010 No impact on commercial strategy expected ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Research & Development/Molecular Diagnostics/Products Subtitle: [...]

Continue reading

Adhoc, Ag Reports, Analytical Instrument, Berlin Germany, Biomarker, Blood Plasma, Cancer Detection, Cancer Patients, Case Control Studies, Commercial Strategy, Control Subjects, Epigenomics, Molecular Diagnostics, Plasma Samples, Preliminary Results, Prime Standard, Seattle Wa, Study Steering Committee, Study Subjects, Testing Laboratories

7,852 subjects prospectively enrolled including more than 50 cancer cases Blood samples selected for testing by independent biostatistics group Septin9 testing in three independent laboratories on track; majority of samples tested Completion of PRESEPT Study and reporting of top-line results expected for early 2010 ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely [...]

Continue reading

Adhoc, Berlin Germany, Biopsy, Biostatistics Group, Blood Samples, Cancer Cases, Clinical Research Study, Colonoscopy, Colorectal, Colorectal Cancer, Epigenomics, Independent Laboratories, Molecular Diagnostics, Pathological Examination, Presept, Prime Standard, Prospective Multi Center, Seattle Wa, Study Subject, Study Subjects

PRESEPT Study evaluates clinical performance and health economic benefit of colorectal cancer screening with mSEPT9 blood test Quest Diagnostics, ARUP Laboratories, and Charité – Universitätsmedizin Berlin selected to test mSEPT9 biomarker in blood plasma samples from PRESEPT Study subjects Laboratories to use recently launched Epi proColon CE Marked IVD test products for the testing of [...]

Continue reading

Arup Laboratories, Biomarker, Blood Plasma, Blood Samples, Cancer Cases, Cancer Screening, Clinical Performance, Colorectal Cancer, Eans, Economic Benefit, Epigenomics Ag, Independent Clinical Laboratories, Medical Research Study, Molecular Diagnostics, Plasma Samples, Quest Diagnostics, Study Samples, Study Subjects, Test Products, Three Quarters